PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Fewer Versus More Neoadjuvant Chemoimmunotherapy Cycles in Resectable Esophageal Squamous Cell Carcinoma

esophageal squamous cell carcinomaneoadjuvant chemoimmunotherapyPD-1 inhibitorsintilimabalbumin-bound paclitaxelnedaplatincycle numberpropensity score matchingretrospective cohortrecurrence-free survivalpathological complete responseoncology pharmacy Oncology Pharmacy

Background Information

Neoadjuvant cycles in esophageal cancer: flexibility or necessity?

Determining optimal neoadjuvant chemotherapy cycles for esophageal squamous cell carcinoma (ESCC) can enhance treatment efficacy and patient outcomes. Post-matching, there was no significant difference in objective response rate (ORR) or pathological complete response (pCR) between 1-2 and 3-4 cycles; both had similar safety profiles. This study suggests no clear advantage of 3-4 cycles over 1-2 cycles of neoadjuvant chemotherapy combined with immunotherapy in ESCC, supporting flexibility in cycle number based on patient factors. 1-2 and 3-4 cycles of neoadjuvant chemotherapy plus immunotherapy show similar efficacy and safety in ESCC.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Lv H, Wang Z, Su C, Wang H, Chen B, Gai C, Liu Y, Ding W, Wang M, Sun K, Zhang F, Zhu Y, Li Z, Tian Z

Citation: Lv H, Wang Z, Su C, et al. Evaluation of the efficacy and safety of different cycles of neoadjuvant chemotherapy combined with immunotherapy in locally advanced esophageal squamous cell carcinoma: a multi-center, real-world study. World journal of surgical oncology. 2026;24(1). doi:10.1186/s12957-026-04514-0

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.